Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | NRAS |
Variant | G12S |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | NRAS G12S is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12S results in increased Erk phosphorylation and cell proliferation, is transforming in culture (PMID: 17823240), and is predicted to lead to a loss of Nras protein function based on the effects of HRAS G12S (PMID: 24224811, PMID: 21850009, PMID: 6330729). |
Associated Drug Resistance | |
Category Variants Paths |
NRAS mutant NRAS act mut NRAS G12S NRAS mutant NRAS exon2 NRAS G12X NRAS G12S |
Transcript | NM_002524.5 |
gDNA | chr1:g.114716127C>T |
cDNA | c.34G>A |
Protein | p.G12S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002524.5 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_002524 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_002524.4 | chr1:g.114716127C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05726864 | Phase Ib/II | ELI-002 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) | Recruiting | USA | 0 |
NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |